ArticleACS pharmacology & translational science2026
Inhibition of Lin-11, Isl-1, and Mec‑3 Kinase (LIMK) Activity Attenuates Astrogliosis and Vascular Remodeling in an Experimental Model of Cuprizone-Induced Demyelination in Mice.
Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A variety of neurological impairments are caused by the loss of myelin, which is a hallmark of demyelinating diseases such as multiple sclerosis (MS). The cuprizone model is a well-established demyelination model in which specific brain regions undergo persistent demyelination after cuprizone administration. LIM kinases (LIMKs), a downstream of the RhoA/ROCK pathway, regulate cytoskeletal reorganization through the depolymerization of actin filaments. In our previous findings, LIMK1's phosphorylation was found to be enhanced during chronic phases of spinal cord injury (SCI), leading to scar formation and neuronal loss. However, the specific implications of the LIMK pathway on demyelination and axonal damage in nontraumatic neurodegenerative disorders remain unresolved. In this study, we explored the differential expressions of phosphorylated LIMK1 (p-LIMK1) in a cuprizone-induced acute and chronic demyelination model and its further correlation with astrogliosis and vascular remodeling. BMS-5, the LIMK inhibitor, alleviated cuprizone-induced demyelination, exerting its therapeutic effects via inhibiting LIMK expression. This resulted in the diminution of astrogliosis marked by reduced glial fibrillary acidic protein (GFAP) and neural/glial antigen 2 (NG2) expression and the subsequent maintenance of myelin integrity. Additionally, BMS-5 treatment was associated with improved motor function. Overall, these findings suggest that LIMK inhibition with BMS-5 holds promise as a therapeutic approach for demyelination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.